G1 Therapeutics' breast cancer drug fails in late-stage trial (updated)

G1 Therapeutics

24/06/2024 12:11

(Adds details and background throughout, share movement in
paragraph 5)
       June 24 (Reuters) - G1 Therapeutics  GTHX.O  said on
Monday its drug for a rare, aggressive form of breast cancer did
not meet the main goal of overall survival in a late-stage
trial. 
        G1's drug trilaciclib was tested in 187 patients with
metastatic triple-negative breast cancer, with the patients who
took the drug showing a median overall survival of 17.4 months,
while patients who did not receive the treatment survived for
17.8 months overall.
    CEO Jack Bailey said G1 will evaluate other uses for
trilaciclib and will pursue partners to expand its use globally
    Last week, AstraZeneca's breast cancer drug, Truqap, in
combination with chemotherapy agent paclitaxel, did not meet its
main goals in a late-stage trial to improve overall survival of
patients.
    Shares of G1 therapeutics fell 31.8% in premarket trading.

 (Reporting by Christy Santhosh; Editing by Tasim Zahid)
 ((Christy.Santhosh@thomsonreuters.com;))